Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Clin Cancer Res. 2008 Nov 15;14(22):7519–7525. doi: 10.1158/1078-0432.CCR-08-0151

Figure 2. T854A mutation reduces inhibition of autophosphorylation of EGFR by erlotinib.

Figure 2

Lysates from 293T cells transiently transfected with cDNAs encoding either EGFR WT, T854A, L858R, or L858R plus T854A and treated with different concentrations of erlotinib were immunoblotted for phospho-EGFR (Y1092), total EGFR, and Actin. T854A reduced the degree of inhibition of phospho-EGFR by erlotinib relative to WT or L858R EGFR. Actin is shown as a loading control.